Physician profile
John David Lilly
NPI 1699816298
$455.68
in general payments reported to CMS, 2019-2025
14 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $13.45 · 2023: $66.50 · 2024: $221 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $442.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $442.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $70.70 | 2023-2025 | Freestyle Libre, Eterna |
| Aimmune Therapeutics, INC. | $61.24 | 2024-2025 | Zenpep |
| Abbvie INC. | $57.71 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.07 | 2022-2024 | Xifaxan |
| Astrazeneca Pharmaceuticals Lp | $35.65 | 2024-2025 | Airsupra |
| Exact Sciences Corporation | $35.14 | 2023-2025 | Cologuard Collection Kit |
| Irhythm Technologies, INC. | $26.52 | 2024 | Zio Xt Patch, Zio Monitor |
| Astellas Pharma US INC | $21.58 | 2024 | Veozah |
| Shield Therapeutics INC | $19.03 | 2024 | |
| Antares Pharma, INC. | $17.49 | 2024 | Xyosted |
| Novo Nordisk INC | $16.77 | 2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $16.66 | 2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $16.28 | 2025 | Vpriv |
| Halozyme INC | $15.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lilly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.